Type 1 Diabetes

In our October 2023 endocrinology month in review, our editorial team highlights regulatory updates, pipeline news, and conference data capturing the attention of the field during the month.

In this episode, hosts discuss the FDA clearance of the Omnipod 5 App for iPhones and a pair of studies examining use of automated insulin delivery systems.

A study from investigators in Italy sheds further light on the relationship between physical activity and diabetic polyneuropathy risk in patients with type 1 diabetes.

In this episode, hosts discuss data from the PROTECT trial, which examined the effects of teplizumab on beta-cell function in patients with newly diagnosed type 1 diabetes.

The FDA has granted 510(k) Clearance to the Omnipod 5 app for iPhone, making Insulet Corporation the first to offer a tubeless AID system with smartphone control.

Exposure to maternal diabetes during pregnancy is associated with an increased risk of depression and anxiety in offspring later in life, according to a new study.

An analysis of more 13,000 children with type 1 diabetes suggests puberty onset in children with type 1 diabetes is occurring earlier now than it had been at the turn of the century.

In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.

Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.

New results from the AiDAPT trial show hybrid closed-loop therapy significantly improves maternal glycemic control during pregnancy complicated by T1D.

Phase 1/2 trial data shows all patients with T1D treated with VX-880 achieved improved glycemic control and a reduction or elimination of external insulin needs.

Our endocrinology month in review for September 2023 spotlights news related to semaglutide and a pair of articles offering a deep dive into comorbidities in type 1 and type 2 diabetes.

A new study from Sweden is calling attention to disproportionate increases in psychotropic medication use among young people with type 1 diabetes relative to their counterparts without type 1 diabetes.

According to the analysis, high-performing primary care practices use similar strategies to manage change and quality improvement in care for people with diabetes.

An analysis of patient data from a health system in southern California suggests both type 1 and type 2 diabetes rates rose among younger populations during the COVID-19 pandemic, affecting non-Hispanic Black and Hispanic youth most significantly.

Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a breakdown of the latest news in diabetes management, including FDA clearance of a new insulin pump and a major acquisition within the diabetes world.

In this episode, hosts sit down for a discussion around a recent NEJM report assessing the effects of semaglutide use in people with type 1 diabetes, including the implications of the findings and their real-world experiences with GLP-1 use in people with type 1 diabetes.

A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.

A 1-year observational follow-up of a 3-month RCT provides insight into he benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.

In this episode, hosts discuss their experience interacting with the Tandem Mobi pump from the ADCES 2023 meeting and offer perspective on what the Welldoc clearances mean for people with diabetes and care providers.

During this episode, hosts are joined by Etty Vider, PharmD, for a nuanced discussion surrounding leveraging diabetes technology to improve care for people with diabetes, including exploring strategies for improving the utilization of diabetes technology, the role of primary care in adoption of these technologies, and how improved uptake correlates to improved outcomes.

Expert endocrinologists provide final thoughts on addressing unmet needs and improving the management of T1D.

Schafer Boeder, MD, and Egils K. Bogdanovics, MD, share approaches to prevention, preservation, and replacement therapies for the treatment of T1D.

In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes.